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Introduction
============

Non-alcoholic fatty liver disease (NAFLD) is defined as fatty infiltration of the liver in the absence of alcohol use or infection with viral hepatitis. NAFLD is a common disorder, affecting 25% of the world population and almost 24%-32% of the population in the western world \[[@REF1]\]. In the USA, NAFLD affects 30% of the population and is the third most common indication for liver transplant \[[@REF2]-[@REF3]\]. This high prevalence of NAFLD is presumably caused by a high-calorie diet and a sedentary lifestyle \[[@REF4]\]. In fact, NAFLD is projected to become the most common cause of end-stage liver disease and liver transplant in the next decade \[[@REF5]-[@REF6]\]. Furthermore, evidence suggests that NAFLD is a multi-system disease that affects the liver and the cardiovascular system leading to structural and functional changes in the heart and the blood vessels. Ultimately these changes are responsible for the increased cardiac morbidity and mortality associated with NAFLD \[[@REF7]-[@REF9]\].

To date, there has been one retrospective study to ascertain the association of NAFLD with conduction defects \[[@REF10]\]. The study demonstrated that patients with right bundle branch block (RBBB) are at higher risk of developing NAFLD due to passive congestion of the liver. We extend this line of thought and postulate that patients with NAFLD are at risk for developing other types of conduction defects. In order to test this hypothesis, we conducted a large population-based case-control study of adult men and women at Orange Park Medical Center (OPMC) in Florida.

Materials and methods
=====================

The study protocol was approved by the OPMC Graduate Medical Education Research committee as a minimal risk study because the study is a retrospective chart review with no patient contact.

Study design
------------

This was a retrospective case-control study designed to test the association between NAFLD and conduction defects (Figure [1](#FIG1){ref-type="fig"}). NAFLD was an incidental finding in patients admitted for other reasons. NAFLD was diagnosed by detection of hepatic steatosis on abdominal ultrasonography (USG) or computerized tomography (CT) scans. Patients were divided into two groups: group-1 included patients who had NAFLD diagnosed on abdominal imaging and group-2 were controls who did not have NAFLD on abdominal imaging. Controls (No-NAFLD) were randomly selected from the general population of hospitalized adult patients, who also had an electrocardiogram (EKG) and abdominal imaging studies performed during hospitalization. All EKGs were interpreted by a cardiologist independent of the study.

Study population
----------------

The study population included adult patients (\>18 years of age) admitted to the OPMC from 2009 to 2015. All patients had abdominal imaging and EKG studies ordered. Based on abdominal imaging, the population was divided into NAFLD versus No-NAFLD cases. Patients were excluded if there was a history of alcohol use, defined as \>21 drinks/week for men and \>14 drinks/week for women. Other exclusions included acute viral hepatitis, chronic viral hepatitis, congenital heart disease, infiltrative malignancy, myocarditis or cardiac surgeries. Also, patients who did not have an abdominal USG, CT scan abdomen or EKG were excluded from the study.

Predictor variables
-------------------

Baseline demographic characteristics collected included age, gender, race, obese, chronic conditions (asthma/chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), diabetes mellitus, hypertension) ischemic heart disease, NAFLD, medication use (beta-blockers, calcium channel blockers, digoxin, amiodarone, adenosine), cirrhosis, thyroid disorders, smoking, cocaine use (Table [1](#TAB1){ref-type="table"}). We did not include body mass index (BMI) in our study due to lack of availability of height in the medical record for most patients.

Outcome variables
-----------------

Conduction defect identified on EKG was the primary outcome variable. The EKG changes for conduction defects were determined by reviewing EKG tracings already verified by a cardiologist. Secondary outcomes for this study included the presence of other EKG changes (for example, atrial fibrillation, premature atrial contractions (PACs), premature ventricular contractions (PVCs), axis deviation, low voltage, prolonged QTc interval, hypertrophy, and ST wave changes).

Statistical analysis
--------------------

Univariate logistic regression analysis was used to assess the association between NAFLD, baseline demographics, clinical characteristics, medicine use, EKG changes, and conduction defects (Table [2](#TAB2){ref-type="table"}). Multivariate logistic regression analysis with backward elimination method was performed to determine if NAFLD is a risk factor for conduction defects from 19 selected predictors/factors (age, sex, race, obesity, coronary artery disease (CAD), hypertension, diabetes mellitus, CHF, smoking, COPD, asthma, thyroid disorder, antipsychotic medicine, hyperlipidemia, and NAFLD) (Table [3](#TAB3){ref-type="table"}). The risk estimates were reported as odds ratios (OR) with 95% confidence intervals (CI). A p-value \< 0.05 was considered statistically significant. R version 3.3.1 (University of Auckland, New Zealand) was primarily used for statistical analysis and SAS 9.4 (SAS Institute Inc., Cary, NC) was used to validate R output.
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Results
=======

A total of 700 patients were included in the study. NAFLD was identified on abdominal imaging in 408 patients. In the No-NAFLD group, there were 292 patients. The median age was 58 years (standard deviation (SD)=15.3 years). There were 293 males (41.9%), and 407 females (58.1%). Most patients were Caucasian (n=534, 76.3%). Other baseline characteristics are listed below (Table [1](#TAB1){ref-type="table"}). A total of 155 conduction defects were identified in 140 patients demonstrated on EKG (Table [4](#TAB4){ref-type="table"}).

###### Demographics and clinical characteristics of the study population

  --------------------- ------------------- ------------------- ------------------- ---------- ------- ----------
                        ALL                 NAFLD               No NAFLD                               
                        N,% or Median, SD   N,% or Median, SD   N,% or Median, SD                      
  Age (median)(SD)      57.9                (15.3)              59                   (13.6)    56.3    (17.5)
  Sex (males)           293                 (41.8%)             178                 (43.6%)    115     (39.4%)
         (females)      307                 (58.2%)             230                  (56.4%)   177      (60.8%)
  Race                                                                                                 
     Caucasian          534                 (76.4%)             318                  (80%)     216      (74.2%)
     African American   98                  (14%)               45                   (11%)     53       (18.3%)
     Hispanic           17                  (0.02%)             16                   (3.9%)    1        (0.3%)
     Other              50                  (0.07%)             29                   (7.1%)    21       (7.2%)
  Smokers               237                 (33.8%)             142                  (34.8%)   96       (32.9%)
  Illicit Drug Users    73                  (10.4%)             46                   (11.3%)   27       (9.3%)
  Hypertensive          421                 (60.1%)             262                  (64.2%)   159      (54.5%)
  CAD                   94                  (13.4%)             45                   (11.0%)   49       (16.8%)
  Hyperlipidemia        230                 (32.8%)             123                  (30.2%)   107      (36.6%)
  Diabetics             224                 (32%)               156                  (38.2%)   68       (23.3%)
  Obese                 339                 (48.4%)             214                  (52.5%)   125      (42.8%)
  CHF                   38                  (0.05%)             23                   (5.6%)    15       (5.1%)
  --------------------- ------------------- ------------------- ------------------- ---------- ------- ----------

Univariate analysis
-------------------

Univariate analysis of EKG findings, (conduction defect, PACs/PVCs, hypertrophy, axis deviation, ST wave changes, low voltage, and QTc prolongation) identified a positive association with NAFLD (p-value \<0.05). Atrial fibrillation showed no association with NAFLD (Table [2](#TAB2){ref-type="table"}).

The proportion of patients with a conduction defect on EKG was higher in patients with NAFLD (107/408, 26.2%) compared to the No-NAFLD group (33/292, 11.3%), (p-value \<0.001). When conduction defects were further stratified (Table [4](#TAB4){ref-type="table"}) into AV block and bundle branch block, AV block was not significantly associated with NAFLD (6.9% in NAFLD vs 3.8% No-NAFLD (p-value 0.0828). However, bundle branch block was significantly associated with NAFLD (22.1% in NAFLD vs 8.9% in No-NAFLD (p-value \<0.001).

###### Univariate analysis of demographics, clinical characteristics, medicine, and EKG changes by NAFLD

TCA - tricyclic antidepressant, SSRI - selective serotonin reuptake inhibitors, CCB - calcium channel blocker.

 

  --------------------------------- ----------------- ----------------- --------------------- ------------ ------------------------------ ----------
  Variables                         NAFLD  (408)      No-NAFLD (292)    Odds ratio (95% CI)    p-value\*                                  
                                    N,% or Mean, SD   N,% or Mean, SD                                                                     
  Mean age, year (SD)               59.0              (13.6)            56.3                  (17.5)       1.01  (1.00-1.02)              0.0203
  Sex (male)                        178               (43.6)            115                   (39.4)       1.19  (0.88-1.62)              0.2619
  Race (African American)           45                (11.0)            53                    (18.2)       0.56  (0.36-0.86)              0.0080
  Smokers (current/former)          142               (34.8)            96                    (32.9)       1.09  (0.79-1.50)              0.5956
  Hypertensive                      262               (64.2)            159                   (54.5)       1.50  (1.11-2.04)              0.0094
  CAD                               45                (11.0)            49                    (16.8)       0.62  (0.40-0.95)              0.0288
  Hyperlipidemia                    123               (30.2)            107                   (36.6)       0.75  (0.54-1.03)              0.0715
  Diabetics Mellitus                156               (38.2)            68                    (23.3)       2.04  (1.46-2.86)              \<0.0001
  Obese                             214               (52.5)            125                   (42.8)       1.47  (1.09-1.99)              0.0120
  CHF                               23                (5.6)             15                    (5.1)        1.11  (0.57-2.16)              0.7676
  Cirrhosis                         73                (17.9)            2                     (0.68)       31.59 (7.69-129.84)            \<0.0001
  COPD                              59                (14.5)            34                    (11.6)       1.28  (0.82-2.02)              0.2798
  Asthma                            12                (2.9)             14                    (4.8)        0.60  (0.27-1.32)               0.2054
  PAC/PVC                           86                (21.1)            29                    (9.9)        2.42  (1.54-3.80)              0.0337
  Thyroid disorder                  78                (19.1)            41                    (14.0)       1.45  (0.96-2.19)              0.0789
  Illicit Drug Users                46                (11.3)            27                    (9.3)        1.25  (0.76-2.06)              0.3874
  Beta Blocker                      130               (31.9)            92                    (31.5)       1.02  (0.74-1.40)              0.9206
  Digoxin                           4                 (1.0)             1                     (0.3)        2.88  (0.32-25.91)             0.3450
  TCA                               13                (3.2)             5                     (1.7)        1.89  (0.67-5.36)              0.2321
  SSRI                              75                (18.4)            37                    (12.7)       1.55  (1.01-2.38)              0.0432
  CCB                               80                (19.6)            59                    (20.2)       0.96  (0.66-1.40)              0.8448
  Antipsychotic                     21                (5.2)             14                    (4.8)        1.08  (0.54-2.16)              0.8339
  Amiodarone                        0                 (0.0)             5                     (1.7)        \<0.001  (\<0.001 - \>999.9)   0.9797
  Adenosine                         0                 (0.0)             0                     (0.0)        NA                             NA
  Atrial fibrillation               45                (11.0)            33                    (11.3)       0.97  (0.60-1.57)              0.9101
  Low Voltage                       57                14.0)             17                    (5.8)        2.63  (1.49-4.62)              0.0008
  QT-prolongation                   93                (22.8)            16                    (5.5)        5.09  (2.92-8.86)              \<0.0001
  ST-change                         195               (47.8)            115                   (39.4)       1.41  (1.04-1.91)              0.0274
        Anterioseptal-ST            49                (12.0)            33                    (11.3)       1.07  (0.67-1.71)              0.7749
        Anteriolateral-ST           45                (11.0)            30                    (10.3)       1.08  (0.66-1.76)              0.7514
        Interior-ST                 33                (8.1)             20                    (6.9)        1.20  (0.67-2.13)              0.5417
        Posterior-ST                3                 (0.7)             0                     (0.0)        \>999 (\<0.01 - \>999.9)       0.9845
        Nonspecific-ST              124               30.4)             50                    (17.1)       2.11  (1.45-3.06)              \<0.0001
  Axis deviation                    91                (22.3)            24                    (8.2)        3.21  (1.99-5.17)              \<0.0001
  Hypertrophy                       91                (22.3)            33                    (11.3)       2.25  (1.46-3.47)              0.0002
  Conduction Defect                 107               (26.2)            33                    (11.3)       2.79  (1.83-4.26)              \<0.0001
       AV block                     28                (6.9)             11                    (3.8)        1.88  (0.92-3.84)              0.0828
       Bundle Branch Block          90                (22.1)            26                    (8.9)        2.90  (1.82-4.61)              \<0.0001
  --------------------------------- ----------------- ----------------- --------------------- ------------ ------------------------------ ----------

Multivariate analysis
---------------------

Multivariate logistic regression with backward elimination identified six risk factors for conduction defects including; NAFLD (OR 2.38; 95% CI 1.51-3.73, p \<0.0001), hypertrophy (OR 2.52; 95% CI 1.57-4.05, p=0.0001), CHF (OR 3.05; 95% CI 1.46-6.38, p=0.0031), male sex (OR 1.79; 95% CI 1.19-2.69, p=0.0051), diabetes mellitus (OR 1.63; 95% CI 1.08-2.47, p=0.02), and age (OR 1.04; 95% CI 1.02-1.06, p\<0.0001) (Table [3](#TAB3){ref-type="table"}).

###### Multivariate logistic regression analysis for conduction defect using backward elimination method

  -------------------------------- --------------------------- ----------------------------- -------------------- --------- ------------------- -----------
  Variables\#                      Conduction Defect   (140)   No-Conduction Defect  (560)   Odds ratio (95%CI)   p-value                       
                                   N,% or Mean, SD             N,% or Mean, SD                                                                  
  Mean age, year (SD)              64.5                        (14.3)                        56.3                 (15.3)    1.04  (1.02-1.06)   \<0.0001
  Sex (male)                       71                          (50.7)                        222                  (39.6)    1.79  (1.19-2.69)   0.0051
  Diabetics Mellitus               62                          (44.3)                        162                  (28.9)    1.63  (1.08-2.47)   0.0205
  CHF                              17                          (12.1)                        21                   (3.8)     3.05  (1.46-6.38)   0.0031
  Hypertrophy                      42                          (30.0)                        82                   (14.6)    2.52  (1.57-4.05)   0.0001
  NAFLD                                  107                   (76.4)                        301                  (53.8)    2.38  (1.51-3.73)   \< 0.0001
  -------------------------------- --------------------------- ----------------------------- -------------------- --------- ------------------- -----------

###### Conduction defect distribution

  ------------------------------------ ---------------- -------------- -------------- --------- ----- -------
  Variables                            No-NAFLD  (33)   NAFLD  (107)   Total  (140)                   
                                       n                \%             n              \%        n     \%
  1^st^ degree AV block                11               7.1            25             16.1      36    23.2
  Mobitz type 1                        0                0.0            3              2.1       3     2.1
  Right bundle branch block            14               9.0            44             28.4      58    37.4
  Left bundle branch block             4                2.6            21             13.5      25    16.1
  Bi-fascicular block                  1                0.6            15             9.7       16    10.3
  Nonspecific intraventricular block   7                4.5            10             6.5       17    11.0
  Total conduction defects             37               23.9           118            76.1      155   100.0
  ------------------------------------ ---------------- -------------- -------------- --------- ----- -------

Discussion
==========

The major finding of this study is that patients diagnosed with NAFLD showed a significant association with conduction defects. This association was independent of numerous other risk factors after adjusting for confounders.

Prior studies have shown associations between NAFLD and CAD \[[@REF11]-[@REF13]\]. However, few studies have evaluated the association of NAFLD with electrical abnormalities of the heart. To our knowledge, this is the first study to evaluate for the presence of conduction defects and describe EKG abnormalities found in patients with NAFLD.

The underlying pathophysiological mechanism responsible for the association between NAFLD and conduction defect is not well understood. NALFD might be a marker for ectopic fat deposition in myocardium and pericardium that promotes cardiovascular disease. A recent study has shown an association between intra-hepatic and myocardial triacylglycerol content and that increased pericardial fat is associated with increased prevalence of atrial fibrillation \[[@REF14]-[@REF15]\]. Further, adipocytes in retrosternal, epicardial tissue have been shown to exert effects on ion currents in rabbit left atria, leading to arrhythmias \[[@REF16]\]. NAFLD may potentially contribute to the development of cardiovascular complications as demonstrated by the increased production of pro-inflammatory cytokines such as C-reactive protein, interleukin-6, tumor necrosis factor -- alpha and prothrombotic factors \[[@REF17]-[@REF18]\]. These markers have been associated with structural changes in the heart and a higher rate of arrhythmias \[[@REF19]-[@REF21]\].

This study has several limitations. First, NAFLD was diagnosed by USG or CT scan, instead of tissue biopsy, the gold standard. Studies have shown that USG has a sensitivity of 60% to 94% and specificity of 84% to 95%, while CT scan has a sensitivity of 82% and specificity of 100%; so neither USG nor CT scan is able to reliably detect hepatic lipid content that is less than 30% \[[@REF22]-[@REF24]\]. Hence, we probably missed mild to moderate cases of NAFLD \[[@REF24]\]. Furthermore, we were unable to differentiate NAFLD from non-alcoholic steatohepatitis, as no tissue biopsy results were available. Second, patients were not primarily admitted for NAFLD, rather NAFLD was an incidental finding identified using International Classification of Diseases, Ninth Revision (ICD-9) codes. Finally, we cannot exclude the effect of unmeasured or unknown confounding factors. For instance, although NAFLD is strongly associated with obesity, we were unable to exclude the confounding effect of BMI on conduction defects due to unavailability of uniformly identifying patient height.

Several studies have demonstrated increased cardiovascular morbidity and mortality in NAFLD patients \[[@REF25]-[@REF26]\]. It is plausible that healthcare providers should treat patients with NAFLD for various cardiovascular risk factors in order to reduce their cardiovascular morbidity and mortality. Lifestyle modification, including weight loss, dietary modifications, and physical activity are the first line treatment for NAFLD and were shown to improve outcomes in patients with NAFLD \[[@REF27]-[@REF28]\]. More recently, thiazolidinediones (pioglitazone and rosiglitazone) and liraglutide were recommended for the management of NAFLD \[[@REF29]-[@REF30]\].

Conclusions
===========

The role of NAFLD as a novel risk factor for cardiac disease has been extensively researched in the last decade. Previous studies have shown an association between NAFLD and structural and metabolic cardiac changes. Still, the data is relatively scarce for the association between NAFLD and arrhythmogenic cardiac abnormalities. Our study suggests that NAFLD is associated with conduction defects. Larger studies are needed to find out the causal relationship as well as the pathophysiological pathways that connect NAFLD and arrhythmogenic abnormalities of the heart.
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